Form 8-K - Current report:
SEC Accession No. 0001683168-20-001071
Filing Date
2020-04-02
Accepted
2020-04-02 17:00:22
Documents
6
Period of Report
2020-03-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT phio_8k.htm 8-K 25947
2 FORM OF COMMON STOCK WARRANT phio_ex0401.htm EX-4.1 113224
3 OPINION OF GIBSON, DUNN & CRUTCHER, LLP phio_ex0501.htm EX-5.1 5658
4 SECURITIES PURCHASE AGREEMENT phio_ex1001.htm EX-10.1 256729
5 GRAPHIC image_1.jpg GRAPHIC 137879
6 GRAPHIC image_002.jpg GRAPHIC 5684
  Complete submission text file 0001683168-20-001071.txt   600749
Mailing Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752
Business Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752 (508) 767-3861
Phio Pharmaceuticals Corp. (Filer) CIK: 0001533040 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36304 | Film No.: 20769955
SIC: 2834 Pharmaceutical Preparations